Screener
10x Genomics, Inc. TXG Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by 10x Genomics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: 10x Genomics, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 6, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054491
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Selling, general and administrative | 78,661 | 74,434 | 145,038 | 164,162 |
| Gain on settlement | (3,400) | (40,700) | (3,400) | (49,900) |
| Total operating expenses | 132,052 | 94,958 | 255,276 | 239,731 |
| Income (loss) from operations | (19,555) | 30,126 | (36,601) | (9,202) |
| Other income (expense): | ||||
| Interest income | 4,797 | 4,271 | 9,811 | 7,957 |
| Interest expense | — | (3) | — | (3) |
| Other income (expense), net | (3,887) | 2,603 | (4,702) | 4,739 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is 10x Genomics, Inc.'s operating income?
- 10x Genomics, Inc. (TXG) reported operating income of -$19.56M in Q2 2026.
- How has 10x Genomics, Inc.'s operating income changed year-over-year?
- 10x Genomics, Inc.'s operating income decreased by 164.9% year-over-year, from $30.13M to -$19.56M.
- What is the long-term trend for 10x Genomics, Inc.'s operating income?
- Over 4 years (2021 to 2025), 10x Genomics, Inc.'s operating income has grown at a 3.9% compound annual growth rate (CAGR), from -$52.25M to -$60.99M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about 10x Genomics, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude